-
Innovation Ranking
NewInnovation Ranking – Praxis Precision Medicines Inc
Praxis Precision Medicines Inc (Praxis) is a clinical-stage biopharmaceutical company that translates genetic insights for the development of novel therapies to treat central nervous system disorders. The company’s pipeline program includes PRAX-114, PRAX-944, PRAXIS-050 and PRAXIS-040 which are molecule GABA receptors for the treatment of psychiatry and movement disorders. Praxis provides programs such as PRAX-562, PRAX-222, PRAX-020, SCN2A-LCF, SYNGAP1, PCDH19, and PRAXIS-030 are used for the treatment of genetic epilepsies. Praxis is headquartered in Cambridge, Massachusetts, the US.
-
Product Insights
NewNet Present Value Model: Praxis Precision Medicines Inc’s Ulixacaltamide
Empower your strategies with our Net Present Value Model: Praxis Precision Medicines Inc's Ulixacaltamide report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Praxis Precision Medicines Inc’s PRAX-628
Empower your strategies with our Net Present Value Model: Praxis Precision Medicines Inc's PRAX-628 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Praxis Precision Medicines Inc’s PRAX-944
Empower your strategies with our Net Present Value Model: Praxis Precision Medicines Inc's PRAX-944 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Praxis Precision Medicines Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Praxis Precision Medicines Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ulixacaltamide Hydrochloride in Essential Tremor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ulixacaltamide Hydrochloride in Essential Tremor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ulixacaltamide Hydrochloride in Essential Tremor Drug Details: Ulixacaltamide hydrochloride (PRAX-944)...
-
Product Insights
Essential Tremor – Drugs In Development, 2023
Global Markets Direct’s, ‘Essential Tremor - Drugs In Development, 2023’, provides an overview of the Essential Tremor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Essential Tremor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Tremor – Drugs In Development, 2023
Global Markets Direct’s, ‘Tremor - Drugs In Development, 2023’, provides an overview of the Tremor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tremor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Epileptic Encephalopathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Epileptic Encephalopathy - Drugs In Development, 2023’, provides an overview of the Epileptic Encephalopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Epileptic Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Trigeminal Neuralgia (Tic Douloureux) – Drugs In Development, 2023
Global Markets Direct’s, ‘Trigeminal Neuralgia (Tic Douloureux) - Drugs In Development, 2023’, provides an overview of the Trigeminal Neuralgia (Tic Douloureux) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Trigeminal Neuralgia (Tic Douloureux), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...